Hosted on MSN5h
Hengrui and Kailera report best-in-class data from Phase II GLP-1/GIP trial
Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...
EurekAlert!1d
Liver cancer burden: global and Chinese perspectives on trends and causes
A new study reveals the rising burden of liver cancer, highlighting the significant impact of metabolic risk factors like ...
Obesity won’t be solely defined by BMI under new plan for diagnosis by global experts
New recommendations on how to define obesity would reduce the emphasis on body mass index and also take into account health problems from extra weight and other measurements.
Reuters28d
Merck signs up to $2 billion deal for oral weight-loss drug with China's Hansoh
The company had previously said it is focused on second- and third-generation opportunities in the space, such as oral versions as well as those with the potential to treat obesity-related conditions.
FiercePharma4d
Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
General Atlantic-backed biotech start-up secures $410mn in initial funding round
The Series A funding round by the start-up, co-founded by executives of Aiolos Bio, the biotech that was sold to GSK last ...